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Programmed death 1 (PD-l, CD279) and its   
ligands PD-L1 (B7-H1, CD274) and PD-L2 
(B7-DC, CD273) are key inhibitory molecules 
in immune regulation (Keir et al., 2008; Pardoll, 
2012). This pathway provides particularly prom-
ising targets for cancer immunotherapy (Topalian 
et al., 2012). There is considerable evidence that 
PD-L2 inhibits immunity by binding to the PD-1 
co-inhibitory receptor (Latchman et al., 2001; 
Zhang et al., 2006). However, several studies have 
shown that PD-L2 can function to stimulate   
T cell proliferation and cytokine production, 
even in PD-1–deficient T cells or with PD-L2 
mutants that did not bind to PD-1 (Liu et al., 
2003; Shin et al., 2003; Wang et al., 2003). These 
findings  suggest  that  PD-L2  may  function 
through a receptor other than PD-1. Most stud-
ies using blocking mAbs show a dominant role for 
PD-L1 in inhibiting immune responses; however, 
PD-L2 plays a dominant role in responses such as 
airway hypersensitivity, experimental allergic con-
junctivitis and nematode infection (Ritprajak 
et al., 2012). In some situations, PD-L2 domi-
nance may be explained by preferential PD-L2 
up-regulation by IL-4, but other instances may 
be explained by the binding of PD-L2 to a re-
ceptor other than PD-1.
Here, we demonstrate that PD-L2 binds to a 
second receptor, repulsive guidance molecule b 
(RGMb). RGMb, also known as DRAGON, 
is a member of the RGM family which consists 
of RGMa, RGMb, and RGMc/hemojuvelin 
(Severyn et al., 2009). RGMs are glycosylphos-
phatidylinositol-anchored membrane proteins 
that bind bone morphogenetic proteins (BMPs) 
and neogenin (Conrad et al., 2010). RGMs do 
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We report that programmed death ligand 2 (PD-L2), a known ligand of PD-1, also binds to 
repulsive guidance molecule b (RGMb), which was originally identified in the nervous 
system as a co-receptor for bone morphogenetic proteins (BMPs). PD-L2 and BMP-2/4 bind 
to distinct sites on RGMb. Normal resting lung interstitial macrophages and alveolar epi-
thelial cells express high levels of RGMb mRNA, whereas lung dendritic cells express PD-L2. 
Blockade of the RGMb–PD-L2 interaction markedly impaired the development of respira-
tory tolerance by interfering with the initial T cell expansion required for respiratory toler-
ance. Experiments with PD-L2–deficient mice showed that PD-L2 expression on non–T cells 
was critical for respiratory tolerance, but expression on T cells was not required. Because 
PD-L2 binds to both PD-1, which inhibits antitumor immunity, and to RGMb, which regu-
lates respiratory immunity, targeting the PD-L2 pathway has therapeutic potential for 
asthma, cancer, and other immune-mediated disorders. Understanding this pathway may 
provide insights into how to optimally modulate the PD-1 pathway in cancer immunother-
apy while minimizing adverse events.
© 2014 Xiao et al.  This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after   
the publication date (see http://www.rupress.org/terms). After six months it is   
available under a Creative Commons License (Attribution–Noncommercial–Share   
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/ 
by-nc-sa/3.0/).
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RESULTS
RGMb binds to PD-L2, but not to PD-L1  
or other related molecules
We identified RGMb as a novel binding partner for PD-L2 
using COS cell expression cloning with PD-L2-Ig fusion pro-
tein. Using flow cytometry with stably transfected 300 cells and 
Ig fusion proteins, we found that mRGMb binds to mPD-L2 
but not mPD-L1 or other proteins of the B7 family (Fig. 1, 
a and b). ELISA with purified proteins showed that mRGMb 
binds to mPD-L2 and hPD-L2, and that hRGMb binds to 
hPD-L2 and mPD-L2 (Fig. 1 c and not depicted). Thus, the 
RGMb–PD-L2 interaction occurs in both mice and humans. 
Further studies showed that PD-L2 does not bind to RGMa 
or RGMc (Fig. 1 d). Biacore data showed that PD-L2 bound 
to RGMb with a similar affinity as to PD-1, Kd = 48.5 and 
58.8 nM, respectively (Fig. 1 e).
not directly signal but can act as co-receptors that modulate 
BMP signaling (Samad et al., 2005). RGMb is expressed and 
functions in the nervous system (Severyn et al., 2009). In ad-
dition, RGMb expression is observed in macrophages and 
other cells of the immune system (Xia et al., 2011). However, 
the function of RGMb in the immune system is only begin-
ning to emerge (Galligan et al., 2007; Xia et al., 2011). RGMb-
deficient mice have an early lethal phenotype (Xia et al., 2011).
Here, we characterize RGMb binding to PD-L2 and iden-
tify RGMb protein expression in mouse hematopoietic cells 
and human cancer cell lines. Based on the critical role of PD-L2 
in lung immune regulation (Akbari et al., 2010; Singh et al., 
2011) and RGMb expression in the lung, we investigated the 
function of RGMb and PD-L2 in respiratory tolerance. Block-
ade of PD-L2 and RGMb interaction prevented the develop-
ment of respiratory tolerance.
Figure 1.  RGMb binds to PD-L2, but not PD-L1 or other related molecules. (a and b) mRGMb- or mPD-L2–transfected 300 cells, untrans-
fected 300 cells, and PD-1–transfected Jurkat T cells were stained with the indicated Ig fusion proteins (red) or control-Ig (blue) and analyzed  
by flow cytometry. MFI, mean fluorescence intensity. (c and d) Binding of mPD-L2-Ig or control-Ig to plates coated with mRGMb-HIS, hRGMb-
HIS, mRGMa-HIS or mRGMc-HIS, was analyzed by ELISA. (e) Biacore analysis of the interaction of RGMb with PD-L2 and of PD-1 with PD-L2.  
(f–k) Cell–cell binding of the indicated transfected cells was analyzed by cell conjugation assay. In f, h, and j, the top panels show the FSC-SSC 
plots and the bottom panels show the corresponding dot plots. g, i, and k show only the dot plots. All data are representative of 2–11 inde-
pendent experiments.JEM Vol. 211, No. 5  945
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We also determined whether mPD-L2 mAbs would block 
PD-L2 interactions with RGMb. We identified one mPD-L2 
mAb, 2C9, that blocked PD-L2–RGMb but not PD-L2–PD-1 
interactions,  and  three  mPD-L2  mAbs,  3.2, TY25,  and 
MIH37, that blocked both PD-L2–RGMb and PD-L2–PD-1 
interactions (Fig. 2, b and c). TY25 and 3.2 share the same ep-
itope, whereas 2C9 recognizes a different epitope (unpublished 
data). The existence of both single and double blocker PD-L2 
mAbs suggests that the PD-1– and RGMb-binding sites on 
PD-L2 are close but distinct. Properties of RGMb and PD-L2 
mAbs are summarized in Table I.
Interactions of RGMb with PD-L2, BMPs, and neogenin
RGMb is known to bind directly to BMP-2/4 (Samad et al., 
2005; Wu et al., 2012). BMPs consist of a family of >20 members 
related to the TGF- family (Bragdon et al., 2011; Yoshioka 
et al., 2012). We analyzed the capacities of RGMb antibodies 
to block RGMb binding to BMP-2/4. 9D1 and 8B2 blocked 
RGMb binding to BMP-2/4 in an ELISA (Fig. 2 d and not 
depicted) and thus are dual blockers of RGMb interactions 
with PD-L2 and BMP-2/4. However, PD-L2-Ig fusion pro-
tein did not block RGMb binding to BMP-2/4 in an ELISA 
To test the RGMb–PD-L2 interaction under more physi-
ological conditions, we used a cell conjugation assay where one 
transfected cell was labeled with a red dye and the other trans-
fected cell with a green dye. The binding of the two cells was 
assessed by flow cytometry and indicated by double positive 
events (yellow dots). As expected, mRGMb cells bound to 
mPD-L2 cells (Fig. 1 f), but not mPD-L1 cells (Fig. 1 g). As 
positive controls, mPD-1 cells bound to both mPD-L2 and 
mPD-L1 cells (Fig. 1, h and i). Negative control binding assays 
had few conjugates (<0.3%; Fig. 1, j and k; and not depicted). 
These results show that mRGMb binds specifically to mPD-L2, 
but not to mPD-L1, and the structural orientation is compatible 
with RGMb and PD-L2 cell surface-to-cell surface binding.
Characterization of RGMb and PD-L2 mAbs
We characterized a panel of mRGMb mAbs and identified 
6 RGMb mAbs showing specificity by flow cytometry on 
mRGMb- and/or hRGMb-transfected 300 cells, ELISA, 
and Western blotting (unpublished data). We identified two 
mRGMb mAbs, 9D1 and 8B2, that blocked interaction of 
RGMb with PD-L2 (Fig. 2 a). These RGMb antibodies 
do not bind to mRGMa or mRGMc (unpublished data).
Figure 2.  Blocking capacities of RGMb and PD-L2 mAbs and a model for RGMb and PD-L2 interactions. (a–c) The blocking capacity of RGMb 
mAbs and PD-L2 mAbs was determined by cell conjugation assay. After cells were stained with dyes, (a) 300-mRGMb cells were incubated with the indi-
cated concentrations of RGMb mAbs before incubation with 300-mPD-L2 cells; (b) 300-mPD-L2 cells were incubated with the indicated concentrations of 
PD-L2 mAbs before incubation with 300-mRGMb cells; or (c) before incubation with 300-mPD-1 cells. (d) mRGMb-HIS was preincubated with mAbs 
or Ig fusion proteins and then added to BMP-4–coated plates. Binding of mRGMb-HIS was detected by anti–penta-HIS-HRP in an ELISA. Similar results 
were seen with BMP-2 (not depicted). (e) mPD-L2-hIgG or control-hIgG were preincubated alone or with monomeric mRGMb-HIS, and then added to 
BMP-4–coated plates. Binding of Ig fusion proteins was detected with anti–hIgG-HRP in an ELISA. Similar results were also seen for BMP-2 (not depicted). 
(f) mNeogenin- or mPD-L2–transfected 300 cells were stained with indicated Ig fusion proteins or control-Ig and analyzed by flow cytometry. (g) Binding 
of 300-mRGMb cells to 300-mPD-L2 or 300-mNeogenin cells was analyzed by cell conjugation assay. Cells stained with a red dye were incubated with 
cells stained with a green dye and binding was measured by flow cytometry. (h) Molecular model depicting PDL2–BMP–BMPR–RGMb–neogenin and 
PD-L2–PD-1 pathways. All data are representative of two or more independent experiments.946 RGMb is a second receptor for PD-L2 | Xiao et al.
effector Rho, triggering cytoskeletal rearrangement (Conrad 
et al., 2007; Bell et al., 2013). We propose that RGMb can form 
a signaling supercomplex of BMP–BMP receptors–RGMb–
neogenin (BBRN supercomplex). We would caution that this 
model pictures all the possible players and not all may be com-
plexed simultaneously. PD-L2 may interact with this BBRN 
supercomplex by binding to RGMb, and modulate these sig-
naling pathways. Fig. 2 h (right) shows PD-L2 binding to 
PD-1, which results in tyrosine phosphorylation of the PD-1 
cytoplasmic domain, recruitment of tyrosine phosphatases, par-
ticularly SHP-2, and attenuation of antigen receptor signals. 
Thus, PD-L2 may participate in three important signaling cir-
cuits, the PD-1, BMP, and neogenin signaling pathways, by 
binding to either PD-1 or RGMb.
RGMb expression in mouse macrophages  
and RGMb protein structure
RGMb mRNA has been reported in mouse lung macrophages, 
macrophage cell line RAW264.7 and myoblast cell line C2C12 
(Xia et al., 2011), but protein expression was not determined. 
We confirmed RGMb mRNA expression (not depicted) and 
showed cell surface expression of RGMb protein on these cell 
lines by flow cytometry using RGMb mAb 9D1 (Fig. 3 a).
We also analyzed RGMb protein expression using RGMb 
mAb 1H6, which Western blots both mouse and human RGMb. 
One major band (37 kD) and one minor band (49 kD) 
were detected in RAW264.7, J774.1, and C2C12 cells as well 
as mRGMb-transfected 300 cells (Fig. 3 b). No such bands 
were observed in 300 cells (Fig. 3 b), consistent with the ab-
sence of RGMb mRNA (unpublished data). Western blot-
ting demonstrated RGMb expression in mouse peritoneal 
macrophages and thioglycollate-induced peritoneal macro-
phages (Fig. 3 c).
Fig. 3 d shows how proteolytic cleavage of RGMb accounts 
for these multiple protein bands. RGMb contains a portion of 
a von Willebrand Factor type D domain with a proteolytic 
cleavage site between Asp171 and Pro172. After cleavage, the 
two fragments of RGMb remain connected by disulfide bonds 
(Severyn et al., 2009). The molecular weight of uncleaved 
RGMb is predicted to be 40 kD, and cleaved RGMb will have 
N- and C-terminal fragments of 13 and 27 kD, respectively. 
Each fragment has one predicted N-linked glycosylation site, 
which should increase the molecular weight of each frag-
ment by 5–10 kD. The 1H6 mAb reacts with an epitope in the   
C-terminal fragment and recognizes the 37-kD cleaved form 
as well as the 49-kD uncleaved form. Our Western blotting 
analysis shows that most native RGMb is the cleaved form.
RGMb can be expressed on the cell surface,  
but is primarily localized intracellularly
Previous studies have reported RGMb in breast and prostate 
tumor cells (Li et al., 2012a,b). We detected RGMb protein 
on the cell surface of human breast cancer cell lines, MDA-
231, SKBR-3, and MCF-7, nonsmall cell lung cancer cell 
line NCI-H226, and renal cancer cell line SN12C (Fig. 4 a), and 
this expression was confirmed by Western blotting (Fig. 4 b). 
(Fig. 2 d and not depicted). These data suggest that the binding 
sites on RGMb for PD-L2 and BMP are close but distinct.
To test if RGMb can bind both PD-L2 and BMP at the 
same time, we performed an ELISA to analyze the binding 
of PD-L2-Ig fusion protein to immobilized BMP-2/4 in the 
presence or absence of RGMb. PD-L2 could not directly bind 
to BMP-2/4, but in the presence of RGMb could form a 
complex with BMP when RGMb and PD-L2-Ig were added 
simultaneously or sequentially to BMP-2/4 (Fig. 2 e and not 
depicted). These data are consistent with RGMb having distinct 
sites for PD-L2 and BMP binding, and show that RGMb has the 
capacity to form a trimeric complex with BMP and PD-L2.
RGMb has also been reported to bind to neogenin (Conrad 
et al., 2010; Bell et al., 2013). Furthermore, neogenin has been 
shown to directly bind BMP-2/4/6/7, and to modulate BMP 
signaling (Hagihara et al., 2011; Tian and Liu, 2013). We 
found  that  soluble  RGMb-mIgG2a  bound  to  neogenin-
transfected 300 cells (Fig. 2 f). RGMb mAbs weakly blocked 
RGMb-mIgG2a binding to neogenin (unpublished data). Sur-
prisingly, cell conjugation assays showed that 300-mRGMb 
cells did not bind to 300-neogenin cells (Fig. 2 g), suggesting 
that the structural orientation of RGMb and neogenin bind-
ing is not compatible with cell to cell binding but can support 
binding in cis on the same cell surface or of soluble RGMb 
to cell surface neogenin.
Model of RGMb interactions
Based on previous studies and our findings, we propose a model 
for RGMb–PD-L2 signaling (Fig. 2 h, left). RGMb directly 
binds to BMP-2 or BMP-4, which bind to type I BMP recep-
tors (BMPR1a, BMPR1b, ACVR1, and ACVRL1) and recruit 
type II BMP receptors (BMPR2, ACVR2a, and ACVR2b; 
Corradini et al., 2009; Yoshioka et al., 2012). Then type II 
BMP receptors phosphorylate type I BMP receptors, which 
phosphorylate Smad1/5/8 or p38 mitogen-activated protein 
kinase (MAPK) and extracellular signal-regulated protein ki-
nase (ERK), leading to downstream target gene transcription 
(Corradini et al., 2009; Xia et al., 2011). RGMs facilitate the uti-
lization of ACVR2a by BMP-2/4. In the absence of an RGM, 
BMP-2/4 preferentially use BMPR2 (Corradini et al., 2009). 
RGMb may also signal through neogenin and downstream 
Table 1.  Blocking capacities of mRGMb and mPD-L2 mAbs
Blocking mRGMb to 
mPD-L2
mPD-L2 
to 
mPD-1
mRGMb to 
mBMP-2/4
mRGMb to 
mNeogenin
mRGMb mAbs
  307.9D1, 307.8B2 Yes N.A. Yes Weak
  307.1H6, 307.9D3,   
  307.5G1
No N.A. No Weak
mPD-L2 mAbs
  GF17.2C9 Yes No N.A. N.A.
  3.2, TY25, MIH37 Yes Yes N.A. N.A.
N.A., not applicable.JEM Vol. 211, No. 5  947
Article
T cells from naive mice (Fig. 4 d). Cell surface RGMb expression 
was not detectable in primary hematopoietic cells by flow cy-
tometry with PE-conjugated RGMb mAb 9D1 (unpublished 
data). RGMb mRNA and protein levels were not up-regulated 
in T cells by CD3 and/or CD28 activation (unpublished data), 
suggesting that RGMb is not a T cell activation molecule. Intra-
cellular flow cytometry staining using PE-conjugated RGMb 
mAb 9D1 did not detect RGMb expression in splenic T cells 
(CD3+), B cells (CD19+), or DCs (CD11c+) from naive mice 
(Fig. 4 e, top), but detected low levels of RGMb expression in   
these cells from mice treated with FMS-like tyrosine kinase 3   
ligand (FLT-3L) to expand DC populations (Fig. 4 e, bot-
tom). Our findings of intracellular RGMb expression are in 
agreement with the intracellular expression seen in confocal   
microscopy of SKBR-3 cells (Fig. 4 c) and immunohisto-
chemical staining of cancer cells (Li et al., 2012a). The intracel-
lular localization of RGMb along with the variability in RGMb 
cell surface expression suggests additional levels of regulation 
of RGMb cell surface expression.
qRT-PCR showed positive RGMb expression in cells from 
lung, spleen, thymus, peripheral, and mesenteric LNs with 
much higher levels of RGMb mRNA in lung cells (Fig. 4 f). 
Western blotting demonstrated RGMb expression in mouse 
lung alveolar macrophages (AMs) and interstitial macrophages 
(IMs; Fig. 4 g).
Lung IMs, alveolar epithelial cells (AECs), and DCs  
may be involved in RGMb–PD-L2 interaction in the lung
PD-L2 blockade has particularly strong effects on immune 
responses in the lung (Akbari et al., 2010; Singh et al., 2011), 
and RGMb is highly expressed in the lung (Fig. 4 f). Notably, 
lung inflammation (pneumonitis) is the most severe adverse 
event reported in human clinical trials of PD-1 mAb (Topalian 
et al., 2012). Therefore, we investigated the roles of PD-L2 
and RGMb, and of RGMb–PD-L2 interactions in a mouse 
model of OVA-induced respiratory tolerance. Lung IMs, but 
not AMs, have been reported to produce high levels of IL-10 
and inhibit LPS-induced maturation and migration of DCs, 
thereby preventing airway allergy in mice (Bedoret et al., 2009). 
In addition, epithelial cells have been shown to interact with 
DCs to maintain respiratory tolerance through production of 
a diverse array of mediators that modulate the activity of DCs 
(Strickland et al., 2010).
To identify the lung cell subsets involved in RGMb–PD-L2 
interaction that regulate respiratory tolerance, we examined 
mRNA expression of RGMb, PD-L2, and related proteins in 
unstimulated lung IMs (F4/80+CD11c), AMs (F4/80+CD11c+), 
DCs (F4/80CD11c+), other cells (F4/80CD11c), as well 
as CD4+  T cells (TCR+CD4+), CD8+  T cells (TCR+CD8+), 
AECs, and tracheobronchial epithelial cells (TECs; Fig. 5, a–i). 
IMs and AECs expressed the highest levels of RGMb, BMP-
2/4, BMP type I receptors (Bmpr1a, Bmpr1b, and Acvr1), BMP 
type II receptors (Bmpr2, Acvr2a, and Acvr2b), neogenin and 
its ligand netrin 1 (Fig. 5, a–e and i). IMs also expressed the 
highest levels of IL-10 (Fig. 5 f). PD-L2 expression on IMs 
and AECs was barely detectable (Fig. 5 g). DCs expressed 
Because a previous immunohistochemical study showed RGMb 
primarily in the cytoplasm of prostate tumor cells (Li et al., 
2012a), we also evaluated the cellular localization of RGMb 
in SKBR-3 cells. Confocal microscopy showed substantial 
amounts of RGMb inside SKBR-3 cells (Fig. 4 c), consistent 
with the published study, but also revealed detectable RGMb on 
the cell surface (Fig. 4 a).
Western blotting showed positive RGMb expression in 
cells from spleen, thymus, purified splenic CD4+, and CD8+  
Figure 3.  RGMb expression in mouse macrophages and RGMb protein 
structure. (a) Flow cytometric analysis of cell surface expression of 
mRGMb and mPD-L2 on indicated cells using PE-conjugated mAbs.  
(b and c) RGMb expression in the indicated cell type by Western blotting 
using mAb 1H6. The loading amount was 60–80 µg/lane except for 0.5 or 
1 µg/lane for 300-mRGMb. MØ indicates macrophages. Thio-MØ indicates 
thioglycollate-induced peritoneal macrophages. (d) Model of RGMb pro-
tein structure. Data in a–c are representative of two or more experiments.948 RGMb is a second receptor for PD-L2 | Xiao et al.
with antigen (Fig. 6 a). We first compared the development 
of respiratory tolerance in WT and PD-L2–deficient mice. 
T cells from WT mice exposed to intranasal OVA were toler-
ized, as indicated by significantly reduced T cell proliferation 
and IL-4 responses compared with control mice that did not 
receive i.n. OVA (Fig. 6 b). Strikingly, PD-L2–deficient mice 
showed resistance to the development of respiratory toler-
ance. T cells from PD-L2–deficient mice that received OVA 
i.n. displayed similar levels of proliferation and IL-4 produc-
tion as T cells from control PD-L2–deficient mice that re-
ceived PBS i.n. Similarly, treatment of WT mice with a PD-L2 
mAb (3.2) that blocks both PD-L2–RGMb and PD-L2–PD-1 
interaction prevented the development of respiratory tolerance, 
resulting in increased proliferation and IL-4 production com-
pared with tolerized mice treated with control mAb (Fig. 6 c). 
These results suggest that PD-L2 is critical for the develop-
ment of respiratory tolerance.
Because PD-L2 can interact with both PD-1 and RGMb, 
we used specific mAbs to evaluate the contribution of RGMb 
readily detectable levels of PD-L2, B7-1, and B7-2, but low 
levels of most other molecules (Fig. 5, a–h). IMs had very dif-
ferent expression profiles than AMs (Fig. 5, a–h). Lung CD4+ 
and CD8+ T cells expressed very low levels of all the molecules 
examined except for PD-1 and PD-L1 (Fig. 5, a–h). These ex-
pression data support our proposed BBRN model with RGMb 
associating in a supercomplex with BMP receptors and/or neo-
genin on IMs and/or AECs, then interacting with PD-L2 on 
DCs (Fig. 2 h).
Blockade of RGMb–PD-L2 interaction inhibits  
the induction of respiratory tolerance
Respiratory tolerance is a state of antigen-specific immuno-
logical nonresponsiveness induced by exposure to innocuous 
antigens inhaled in the respiratory tract. To induce tolerance, 
mice were exposed intranasally (i.n.) to OVA or PBS control 
on days 0, 1, and 2. Mice were challenged by immunization 
with OVA in ALUM i.p. on day 12, and splenic T cell responses 
were examined 1 wk later by in vitro restimulation of T cells 
Figure 4.  RGMb can be expressed on the cell surface but is primarily localized intracellularly. (a) RGMb cell surface expression on human breast 
cancer cell lines (MDA-231, SKBR-3, and MCF-7), the nonsmall cell lung cancer cell line NCI-H226, and the renal cancer cell line SN12C was analyzed by 
flow cytometry with mAb 1H6 (red) or isotype control (blue). (b) RGMb expression by Western blotting using mAb 1H6. The loading amount was 
60–80 µg/lane except for 0.5 µg/lane for 300-hRGMb. (c) SKBR-3 cells were stained for RGMb (1H6-biotin) or isotype control plus streptavidin-Alexa 
Fluor 488 (green), and then with Phalloidin-TRIC to label F-actin, and analyzed by confocal microscopy. Bars, 25 µm. (d) RGMb expression by Western 
blotting using mAb 1H6. The loading amount was 60–80 µg/lane, except for 0.5 µg/lane for 300-mRGMb cells. (e) Splenocytes from naive mice and mice 
treated with FLT-3L as well as 300-mPD-L2 cells (negative control) were stained for surface markers CD3, CD19, and CD11c. Then intracellular flow cytometry 
staining with PE-conjugated RGMb mAb 9D1 (red) or rat IgG2a (blue) was used to analyze RGMb expression in these cells. (f) RGMb expression in unstimu-
lated cells from the indicated mouse organs by qRT-PCR. Data are mean ± SEM; n = 2; *, P < 0.05; **, P < 0.01. Ordinary one-way ANOVA followed by 
Dunnett’s multiple comparison test. (g) RGMb expression in lung AM and IM by Western blotting as in d. All data are representative of two or more experiments.JEM Vol. 211, No. 5  949
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airway hyperreactivity (AHR), a cardinal feature of asthma. 
Previous work has shown that tolerization via i.n. administra-
tion of OVA can protect from OVA-induced AHR. We ex-
posed mice to OVA i.n. or PBS control, and then immunized 
with OVA in ALUM i.p., challenged with OVA i.n. on days 
20–22, and assessed for the development of AHR on day 23 
(Fig. 6 e). As expected, mice that received PBS i.n. (nontoler-
ized) developed high levels of AHR measured as airway resis-
tance (RL) and dynamic compliance (Cdyn) in anesthetized, 
tracheostomized, and mechanically ventilated mice. Admin-
istration of OVA i.n. induced respiratory tolerance, such that 
the tolerized mice were protected and developed only mild 
levels of AHR. However, treatment of the mice with RGMb 
in development of respiratory tolerance. We treated mice that 
received OVA i.n. with RGMb mAb 9D1 (blocks RGMb–
PD-L2 and RGMb–BMP) or with PD-L2 mAb 2C9 (blocks 
RGMb–PD-L2 but not PD-1–PD-L2) or with isotype con-
trol mAb. Administration of either 2C9 or 9D1 mAb inhibited 
the development of respiratory tolerance and led to higher lev-
els of T cell proliferation and IL-4 production compared 
with control mAb-treated mice (Fig. 6 d). These results sup-
port a role for the RGMb–PD-L2 interaction in promoting 
the development of respiratory tolerance.
To further evaluate the effects of the RGMb–PD-L2 in-
teraction in tolerance, we rechallenged mice that were exposed 
to antigen i.n during RGMb or PD-L2 blockade, and evaluated 
Figure 5.  Expression of RGMb, PD-L2, BMPs, BMPRs, and related molecules in resting lung cell populations and airway epithelial cells. Expres-
sion of indicated mRNAs in resting lung cell populations and airway epithelial cells by qRT-PCR. (a–h) IMs (F4/80+CD11c), AMs (F4/80+CD11c+), DCs  
(F4/80CD11c+), and other cells (F4/80CD11c) were sorted from lung cells pooled from five to eight mice; CD4+ T cells (TCR+CD4+) and CD8+ T cells 
(TCR+CD8+) were sorted from lung cells pooled from two mice. (i) AECs and TECs were pooled from three and eight mice, respectively. Data are mean ± SEM; 
n = 3; *, P < 0.05; **, P < 0.01; ***, P < 0.005; ****, P < 0.001. Ordinary one-way ANOVA followed by Dunnett’s multiple comparison test. All data are repre-
sentative of two or more experiments.950 RGMb is a second receptor for PD-L2 | Xiao et al.
Figure 6.  PD-L2 or RGMb blockade inhibits induction of respiratory tolerance. (a) Experimental protocol for induction of respiratory tolerance. 
(b–d) PD-L2–deficient or WT mice in b, and WT mice injected with the indicated mAb in c and d, were exposed to OVA i.n. (tolerized) or PBS (nontolerized) and 
subsequently received 50 µg OVA/ALUM i.p. T cell proliferation (top) and IL-4 production (bottom) in response to restimulation with OVA in vitro are shown.  
n = 2–3. Data are representative of two to five experiments. Data are mean ± SEM, *, P < 0.05; **, P < 0.01; ***, P < 0.005. (b, top) two-way ANOVA fol-
lowed by Tukey’s multiple comparisons test. (c, top, and d) Two-way ANOVA followed by Dunnett’s multiple comparison test. (b and c, bottom) Two-tailed 
Student’s t test. (e) Experimental protocol used in f and g. (f) WT mice injected with the indicated mAb were exposed to OVA i.n. or PBS, immunized with 
50 µg OVA/ALUM i.p. Mice were subsequently challenged with OVA i.n. on three consecutive days and assessed for AHR by measuring lung resistance (RL) and 
dynamic compliance (Cdyn). Data are the mean ± SEM of 4 mice/group. (g) Lung histopathology of mice from panel f. Lung tissue was stained with H&E 
and analyzed for cell infiltration. Data in f and g are representative of two experiments.JEM Vol. 211, No. 5  951
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the second administration of OVA i.n. Previous work had 
shown that OVA-primed mice express high levels of PD-L2 
on lung DCs and macrophages. The number and intensity 
of PD-L2–positive cells in the lung were examined 48 h later 
using a PD-L2 mAb (TY25) that recognizes a different epitope 
than mAb 2C9. Under these inflammatory conditions, PD-L2 
was expressed by alveolar macrophages (F4/80+CD11c+) and 
about half of dendritic cells (F4/80CD11c+) and interstitial 
macrophages  (F4/80+CD11clo). The  PD-L2  intensity  and 
number of cells was not different in mice treated with mAb 
2C9 (Fig. 8, b and c), indicating that treatment with mAb 
2C9 did not deplete PD-L2–expressing cells. Similarly, treat-
ment of mice with RGMb mAb 9D1 did not deplete these 
populations (not depicted).
Blockade of RGMb–PD-L2 interaction  
impairs T cell expansion to antigen
Previous studies of respiratory tolerance showed that intrana-
sal administration of antigens such as house dust mite (Hoyne 
et al., 1996) or OVA (Tsitoura et al., 1999; Albacker et al., 2012) 
resulted in a strong transient CD4+ T cell response, followed 
by deletion of most of the antigen-specific T cells, with a small 
population of unresponsive T cells remaining. Inhaled anti-
gen is sampled by immature DCs in the lung, which migrate 
to the draining mediastinal LNs, where they encounter antigen-
specific T cells. In the absence of inflammatory stimuli, DCs 
induce transient antigen-specific T cell activation followed by 
T cell deletion and unresponsiveness (Hawiger et al., 2001). 
Respiratory tolerance involves multiple mechanisms includ-
ing deletion of antigen-specific T cells, the development of 
anergy and regulatory T (T reg) cells and these processes may 
occur concurrently (Holt and Upham, 2004; GeurtsvanKessel 
and Lambrecht, 2008; Bedoret et al., 2009; Albacker et al., 
2012). To explore the mechanism whereby RGMb and PD-L2 
interaction enhances respiratory tolerance, we examined the 
effect of blocking RGMb–PD-L2 interaction on the activa-
tion and expansion of transferred OVA-specific DO11.10 
CD4+ T cells. Recipient mice were treated with RGMb mAb 
9D1 or control mAb, subsequently given OVA or PBS i.n. on 
days 0, 1, and 2, and the fate of DO11.10 T cells was monitored 
using the clonotypic mAb KJ1-26 (Fig. 9 a). As expected, ex-
posure of the mice to i.n. OVA resulted in marked expansion 
of the DO11.10 cells in the mediastinal LN on day 7 com-
pared with mice that received i.n. PBS. Notably, this expansion 
of KJ1-26+ T cells was greatly diminished in tolerized mice 
treated with anti-RGMb compared with the control mAb 
treated mice (Fig. 9 b, left). The number of OVA-specific 
T reg cells (KJ1-26+ Foxp3+) was similarly reduced in RGMb 
mAb-treated mice, indicating that the reduced expansion of 
KJ1-26+ T cells was not due to increased numbers of OVA-
specific T reg cells (Fig. 9 b, right).
We next examined the effect of RGMb mAb on the ex-
pansion of KJ1-26+ T cells at earlier time points. Similar num-
bers of KJ1-26+ cells were detected in LNs of RGMb mAb 
and control treated mice on day 3. However, by day 5 the num-
ber of KJ1-26+ cells increased in the control mice, but showed 
mAb 9D1 or with PD-L2 mAb 3.2 abolished the induction 
of tolerance, and upon rechallenge with OVA, these mice de-
veloped severe AHR which was comparable to that of non-
tolerized mice (Fig. 6 f). The lungs of tolerized mice showed 
low levels of cellular infiltration surrounding the airways in 
contrast to nontolerized mice, which showed substantial air-
way inflammation. Mice treated with PD-L2 mAb or RGMb 
mAb demonstrated even more extensive cellular infiltration 
than nontolerized mice (Fig. 6 g). Thus, respiratory tolerance 
promoted by RGMb–PD-L2 interaction protects against the 
development of airway hyperreactivity and lung inflamma-
tion after antigenic challenge.
To determine if RGMb blockade would impact systemic 
immunization, mice treated with RGMb mAb were immu-
nized in the footpad with OVA in IFA, and T cell responses 
in the draining lymph nodes were evaluated 9 d later. There 
were no differences in proliferation, IL-4 or IFN- produc-
tion between mice treated with RGMb mAb 9D1 or control 
mAb (unpublished data). These results demonstrate that treat-
ment with RGMb mAb does not have a global impact on 
in vivo immune responses.
Tolerized mice have fewer OVA-responsive T cells  
than control mice or RGMb mAb-treated mice
To further understand the mechanisms underlying this model of 
respiratory tolerance induction and how blockade of RGMb–
PD-L2 interaction abrogates tolerance in this model, we com-
pared the number and phenotype of T cells responding to 
challenge with OVA after tolerance induction in the presence 
or absence of RGMb mAb. Splenocytes from RGMb mAb-
treated and control mice were labeled with CFSE before cul-
ture with OVA. Tolerized mice had a lower percentage of 
proliferating OVA-specific CD4+ T cells (CFSE low cells) 
than nontolerized mice (Fig. 7, a and b). Treatment with 
RGMb mAb prevented tolerance induction, as shown by a 
restoration of the percentage of CD4+ T cells proliferating to 
OVA to levels observed in nontolerized mice. Cells from to-
lerized mice produced less IL-4, IL-5, and IFN- than nontoler-
ized mice, whereas cells from tolerized, RGMb mAb-treated 
mice had the same high levels of cytokine as nontolerized 
mice (Fig. 7 c). Cytokine production per cell was calculated 
by dividing total IL-4 or IFN- production by the number of 
responding (CFSE low) T cells. No significant differences were 
found in cytokine per cell between nontolerized, tolerized, 
and tolerized plus RGMb mAb-treated groups at 250 g/ml 
OVA in culture (Fig. 7 d). Thus, tolerization primarily affects 
the quantity of responsive T cells. These data suggest that the 
primary mechanism of tolerance in this model is deletion or 
anergy of OVA-specific cells and that treatment with RGMb 
mAb during tolerance induction impairs this process.
Lung macrophages and DCs are not depleted  
by treatment with PD-L2 or RGMb mAbs
To determine if PD-L2 mAb 2C9 inhibited tolerance induc-
tion by depleting PD-L2–expressing cells, mice primed with 
OVA in ALUM were treated with mAb 2C9 on the day of 952 RGMb is a second receptor for PD-L2 | Xiao et al.
expansion of WT KJ1-26+ T cells after transfer to PD-L2–
deficient or WT mice and exposure to OVA i.n. Between days 3 
and 5, the WT KJ1-26+ cells underwent a 72-fold expansion in 
WT recipients but only a 9.7-fold expansion in PD-L2/ 
recipients (Fig. 9 f), indicating a requirement for PD-L2 ex-
pression on non–T cells. Consistent with this, DO11.10 T cells 
from PD-L2/ and WT mice expanded similarly when trans-
ferred to WT mice (Fig. 9 g). These experiments demonstrate 
the importance of PD-L2 expression on non–T cells for the 
initial expansion of T cells to OVA i.n.
To determine the involvement of the PD-1–PD-L2 versus 
RGMB–PD-L2 pathways in this process, mice were treated with 
PD-L2 mAb 2C9, which blocks only the RGMb–PD-L2 in-
teraction or with control mAb. The expansion of KJ1-26+ cells 
on day 5 was significantly reduced in mice treated with mAb 
2C9 compared with control-treated mice (Fig. 9 h), suggest-
ing that PD-1 is not required for this effect because 2C9 does 
not block the interaction of PD-L2 with PD-1. Together, these 
data indicate that blocking RGMb–PD-L2 interaction prevents 
the induction of respiratory tolerance, and does so by reduc-
ing the initial expansion of CD4+ T cells in response to OVA 
by a pathway that does not involve PD-1.
We then examined the effects of blocking PD-L1 or PD-1 
compared with PD-L2 on the initial activation and expan-
sion of transferred DO11.10 OVA-specific CD4+ T cells. On 
day 5, mice treated with the blocking PD-L1 mAb 9G2 or 
PD-1 mAb 1A2 had substantially higher numbers of KJ1-26+ 
cells in the mediastinal LNs than control mAb-treated mice 
little expansion in the RGMb mAb-treated group (Fig. 9 c). 
These findings suggest that blockade of RGMb inhibits the 
induction of tolerance by impairing the expansion of T cells 
that normally occurs after respiratory administration of OVA.
To determine if treatment with PD-L2 mAb would simi-
larly inhibit the response of OVA-specific CD4+ T cells after 
exposure to OVA i.n., mice were treated with PD-L2 mAb, 
RGMb mAb, or control mAb and the number of KJ1-26+ 
cells examined on day 5. Reduced numbers of KJ1-26+ cells 
were detected in both PD-L2 mAb and RGMb mAb-treated 
groups compared with control mAb-treated mice, indicating 
that expansion of KJ1-26+ cells was inhibited (Fig. 9 d). To 
determine if anti–PD-L2 mAb was altering the time course 
of the T cell response, we examined the in vivo response of 
DO11.10 T cells to i.n. OVA over a 9-d period in mice treated 
with PD-L2 mAb or control mAb (Fig. 9 e). In control mAb-
treated mice, the number of KJ1-26+ cells in mediastinal LNs 
increased substantially after day 3, peaking at day 5 and de-
clining thereafter with a small but detectable population re-
maining on day 9, as previously described (Tsitoura et al., 1999). 
In mice treated with PD-L2 mAb, a limited increase in the 
number of KJ1-26+ cells was observed between days 3 and 5 
that was significantly lower than the increase observed in control 
mAb treated mice. Numbers subsequently declined, indicat-
ing that blocking PD-L2 inhibited the expansion of OVA-
specific T cells throughout the response.
We then determined if expression of PD-L2 on  T cells, non-T 
cells, or both was required for T cell expansion. We compared   
Figure 7.  Tolerized mice have fewer OVA-
responsive T cells than control mice or RGMb 
mAb–treated mice. B cell–depleted splenocytes 
prepared on day 19 from mice treated as in Fig. 6 a 
were labeled with CFSE and cultured with OVA for 
4 d. Cells were stained for CD3 and CD4 and sub-
gated on CD3+CD4+ cells for analysis of CFSE 
dilution. (a) Flow cytometry plots show data from 
one representative mouse and (b) shows mean ± 
SEM of three mice/group. (c) On day 4, cultures 
were harvested as in panel a and supernatants 
were collected and assayed for cytokine produc-
tion. Total IL-4, IL-5, and IFN- in culture super-
natants is shown. (d) Cytokine per cell was 
calculated as total cytokine amount in superna-
tant divided by the number of CFSE low cells. 
Data are mean ± SEM; **, P < 0.01; ***, P < 0.005; 
n = 3, Student’s t test. Data are representative of 
two experiments.JEM Vol. 211, No. 5  953
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mechanism and outcome of other PD-L2 interactions is unclear. 
Our data show that the RGMb–PD-L2 interaction promotes 
the development of respiratory tolerance, as PD-L2 or RGMb 
blockade abrogated the induction of respiratory tolerance. The 
RGMb–PD-L2 interaction facilitates the initial T cell expan-
sion in draining LNs during respiratory tolerance induction 
(co-stimulatory function) because PD-L2 or RGMb block-
ade leads to greatly reduced T cell numbers between days 3–7 
after tolerance induction. This expansion is required for tol-
erance induction and is followed by deletion of Ag-specific 
T cells. The outcome of PD-L2 or RGMb blockade is that the 
T cells are not tolerized, thus the final effect of the RGMb–
PD-L2 interaction could be interpreted as co-inhibitory. There-
fore, PD-L2 could have both co-stimulatory and co-inhibitory 
functions depending on the receptor and context, as illustrated 
by the network of multiple interactions shown in Fig. 2 h. In 
this network model, PD-L2 bridges PD-1, BMP, and neogenin 
signaling pathways, accounting for the multifaceted functions 
of its components.
Our data on RGMb and PD-L2 pathway expression in lung 
cell populations, together with previous findings (Bedoret et al., 
2009; Strickland et al., 2010) suggest that IM, AECs, and DCs 
are involved in the induction of respiratory tolerance. We pro-
pose that RGMb on IMs and/or AECs forms a BBRN super-
complex with BMP-2/4, BMP receptors, and neogenin and 
interacts with PD-L2 on DCs. This may signal directly or in-
duce the production of mediators such as IL-10 in IMs or AECs 
to inhibit the maturation and migration of DCs, thereby pro-
moting respiratory tolerance. In support of this, our data show 
that PD-L2 expression on non-T cells provides the required 
signal for the induction of respiratory tolerance because WT 
T cells transferred into PD-L2–deficient mice do not undergo 
the initial T cell expansion involved in tolerance induction. BMP 
signaling could be involved in the induction of respiratory 
tolerance, as the RGMb mAb 9D1 that blocks both RGMb–
PD-L2 and RGMb–BMP-2/4 interactions impaired respira-
tory tolerance.
Components of the BBRN complex have been shown 
to have immune function. Previous studies have shown that 
BMP signaling has immunoregulatory effects on T cells (Graf 
et al., 2002; Hager-Theodorides et al., 2002; Lu et al., 2010; 
Yoshioka et al., 2012). BMP-7 was recently shown to be an in-
structive factor for Langerhans cell differentiation (Yasmin 
et al., 2013). Elevated BMP/Smad signaling has been found 
during airway inflammation (Rosendahl et al., 2002). RGMb-
mediated BMP signaling was reported to inhibit IL-6 pro-
duction by lung macrophages (Xia et al., 2011). Neogenin has 
been shown to be involved in pulmonary inflammation and 
acute inflammatory peritonitis (König et al., 2012; Mirakaj 
et al., 2012), so neogenin signaling could also be involved in 
the induction of respiratory tolerance. RGMb interaction with 
neogenin has been shown to control aggregation and migration 
of neogenin-positive neuroepithelial cells (Conrad et al., 2010). 
Another member of the RGM family, RGMa, was also highly 
expressed in IMs and AECs (Fig. 5, a and i), and was shown 
to be involved in immune responses (Muramatsu et al., 2011). 
(Fig. 9, i and j), which indicated that PD-1 or PD-L1 block-
ade significantly increased the expansion of OVA-specific 
T cells in response to OVA i.n. In contrast, PD-L2 mAb 
treatment led to significantly lower numbers of KJ1-26+ cells 
than in control mAb-treated mice (Fig. 9 j). These data further 
suggest that RGMb–PD-L2 interaction reduces the initial 
expansion of CD4+ T cells in response to OVA by a pathway 
that does not involve PD-1.
DISCUSSION
Here, we demonstrate that RGMb is a novel binding partner 
of PD-L2, and that this interaction regulates the development 
of respiratory tolerance in the lung. PD-L2 has been reported 
to have co-stimulatory or co-inhibitory function (Latchman 
et al., 2001; Tseng et al., 2001; Liu et al., 2003; Shin et al., 
2003; Wang et al., 2003; Pfistershammer et al., 2006; Zhang 
et al., 2006). There is now substantial agreement that the 
PD-1–PD-L2 interaction inhibits immune activation but the 
Figure 8.  Impact of RGMb–PD-L2 blockade on tolerance induction 
is not caused by depletion of APC. (a–c) Mice immunized with OVA 
in ALUM on day 0 received OVA i.n. on days 7–9 and were treated with 
PD-L2 mAb 2C9 or isotype control (500 µg i.p.) on day 8. Lung cells were 
dispersed on day 10 and the expression of PD-L2 analyzed on AMs 
(F4/80+CD11c+), DCs (F4/80CD11c+), and IMs (F4/80+CD11clo). (a) Gating 
strategy used in b–d. (b) Solid line indicates staining with PD-L2 mAb 
TY25; shaded histogram indicates isotype control. One mouse/group rep-
resentative of three is shown. (c) The number of PD-L2+ macrophages and 
DCs was quantified. Data are representative of two experiments.954 RGMb is a second receptor for PD-L2 | Xiao et al.
molecular details of the cross-talk between the components of 
the BBRN signaling supercomplex remain to be determined.
Though early work emphasized the restricted expression 
of PD-L2 on DCs and macrophages, recent work has identi-
fied PD-L2 expression on human primary nasal epithelial cells 
(Kim et al., 2005), Th2 cells (Lesterhuis et al., 2011), activated 
T cells (Messal et al., 2011), and some B cell subsets (Zhong 
and Rothstein, 2011). In the BBRN model, PD-L2 on any of 
these cells might interact with RGMb on various cells and 
signal through BMP and/or neogenin pathways.
Antibodies blocking the PD-1 pathway have shown prom-
ising results in cancer immunotherapy clinical trials. The most 
severe adverse event with PD-1 mAb treatment is pneumoni-
tis (3%) leading to 3 deaths (1%; Topalian et al., 2012). The role 
of the different PD-1 ligands in pneumonitis is not yet under-
stood. PD-1 blockade may shift the balance in PD-L2 inter-
action with its binding partners, increasing PD-L2 availability 
for binding to RGMb, leading to pneumonitis. Additional 
work will need to be done to distinguish which therapeutic 
Because our mRGMb mAb does not bind to mRGMa, the 
effects of our RGMb mAb on respiratory tolerance are inde-
pendent of RGMa.
Our model suggests that PD-L2 binding to RGMb could 
signal through BMP and/or neogenin signaling pathways. 
This hypothesis may offer insight into the signaling conundrum 
of RGMb and PD-L2, i.e., RGMb and PD-L2 do not ap-
pear to be able to signal directly because RGMb is a glyco-
sylphosphatidylinositol-anchored protein and PD-L2 has only a 
short cytoplasmic tail without obvious signaling motifs. To 
signal, RGMb–PD-L2 may need to form a complex with BMPs,   
BMP receptors, and/or neogenin. BMP and neogenin signaling 
may act together because neogenin can directly bind BMP-2/ 
4/6/7 and modulate BMP signaling (Hagihara et al., 2011;   
Tian and Liu, 2013). Nevertheless, these two signaling path-
ways may also function separately because a recent study showed   
that RGMb induces apoptosis in mouse renal tubular epithe-
lial cells through neogenin and not the BMP pathway (Liu et al.,   
2013). RGMb is the pivot joining all these proteins, but the 
Figure 9.  Blockade of PD-L2–RGMb interaction reduces the initial expansion of antigen-specific T cells after intranasal OVA administra-
tion. (a) Experimental protocol for Fig. 9. Mice received DO11.10 T cells on day 0 and OVA i.n. The number of KJ1-26+ cells in mediastinal LNs was deter-
mined on the indicated days. (b) Mice treated with RGMb mAb 9D1 or control mAb on day 1 received 5 × 106 DO11.10 T cells. Left, TCR+ KJ1-26+ 
CD4+; Right, FoxP3+ TCR+ KJ1-26+ CD4+ cells. For each group, mediastinal LNs of 3–5 mice were combined; data are representative of two experiments. 
(c–e) Mice received 2 × 105 DO11.10 T cells after (c) RGMb mAb 9D1 or control mAb; (d) RGMb mAb 9D1, PD-L2 mAb 3.2, or control mAb; (e) PD-L2 mAb 
3.2 or control mAb. (f) WT DO11.10 T cells were transferred into WT or PD-L2/ mice; (g) WT or PD-L2/ DO11.10 T cells were transferred into WT mice. 
(h–j) Mice received 2 × 105 DO11.10 T cells after (h) PD-L2 mAb 2C9 or control mAb; (i) PD-L1 mAb 9G2 or control mAb; (j) PD-L2 mAb 3.2, PD-1 mAb 
1A12, or control mAb. The number of KJ1-26+ T cells in mediastinal lymph nodes on day 5 (h–j) was determined by flow cytometry. (b–d) Each point rep-
resents a pool of LNs from three mice. Data are representative of two to four experiments. (e–j) Each point represents the mean and SEM of KJ1-26+ T cells in 
LNs of two or three groups of two mice each. Data are representative of two experiments. **, P < 0.01; ***, P < 0.005, two-tailed Student’s t test.JEM Vol. 211, No. 5  955
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transfected into COS cells and binding of PD-L2-Ig to RGMb was verified 
by flow cytometry on mRGMb transiently transfected COS cells. At least 
four independent mRGMb cDNA clones were isolated.
Generation of antibodies. Rats were immunized three times via intramus-
cular and intravenous injection of mRGMb plasmid cDNA (Latchman et al., 
2001), and boosted three times with recombinant mRGMb-HIS (R&D Sys-
tems) via i.p. and s.c. injection. Hybridoma supernatants were screened by 
flow cytometry on mRGMb transfected 300 cells or ELISA on plates coated 
with recombinant mRGMb (R&D Systems). Hybridomas were subcloned 
to stability, and antibodies were purified from culture supernatants by protein 
G affinity chromatography, and verified to have endotoxin levels less than 
2EU/mg protein. Clones 307.9D1 (rat IgG2a) and 307.1H6 (rat IgG2a) were 
selected for use in this study.
Generation of Ig fusion proteins. mRGMb-Ig fusion proteins were gener-
ated by joining the extracellular domain of mRGMb to the Fc portion of 
mouse IgG2a protein, mutated to reduce FcR binding (Latchman et al., 2001). 
mPD-L2-hIgG1/IgA fusion proteins were generated by joining the extracel-
lular domain of PD-L2 with the Fc portion of hIgG1 and the tail piece of hIgA 
(Hirano et al., 2006). Fc fusion proteins were purified from CHO cell culture 
supernatants by protein A or protein G affinity chromatography and verified 
to have endotoxin levels less than 2 EU/mg protein. Other Ig fusion proteins 
used have been described previously (Latchman et al., 2001).
Cell conjugation assay. An assay for cell surface receptor-ligand binding was 
developed based on cell–cell binding as determined by flow cytometry. Cells 
transfected with cell surface gene 1 were labeled with the red dye PKH26 
(Sigma-Aldrich), and cells transfected with cell surface gene 2 were labeled 
with the green dye PKH67 (Sigma-Aldrich). Red dye-labeled and green dye-
labeled cells (105 each cell type) were incubated in 200 µl of HBSS buffer 
without calcium and magnesium (Invitrogen) supplemented with 10% heat-
inactivated FBS (Invitrogen), 15 µg/ml gentamicin (Invitrogen), and 1% Hepes 
(Invitrogen) in a round-bottom 96-well plate for 45 min at 37°C. Conjugate 
formation was analyzed immediately by flow cytometry using the PE channel 
for the red dye and the FITC channel for the green dye. The automated plate 
harvester of the FACSCanto (BD) was used for uniformity of cell processing. 
The instrument settings were as follows: throughput mode, standard; loader 
settings, sample flow rate at 0.5 µl/second; sample volume and mixing volume 
at 100 µl; mixing speed at 50 µl/second; number of mixes at 2; and wash vol-
ume at 400 µl. When the cell conjugation assay was used to test the blocking 
capacity of antibodies, the relevant transfected cell was preincubated 30 min 
at room temperature with antibodies before adding candidate binding cells.
Flow cytometry. Cells were stained with target antibodies and isotype controls 
using standard flow cytometry procedures, and analyzed on a FACSCanto 
(BD) using FlowJo 9.2 software (Tree Star).
To initially verify RGMb expression on mRGMb- or hRGMb-transfected 
cells, sheep anti-mRGMb (R&D Systems) or sheep IgG (SouthernBiotech) 
plus donkey anti–sheep IgG-PE (Jackson ImmunoResearch Laboratories) 
and mouse anti-hRGMb (mAb; R&D Systems) plus goat anti–mouse IgG-PE 
(SouthernBiotech) were used, respectively, all at 10 µg/ml.
To test the binding specificities of mRGMb antibodies, mRGMb- or 
hRGMb-transfected 300 cells were incubated with serial dilutions of sera, 
culture supernatants, or purified antibodies, and binding was detected with 
5 µg/ml of goat anti–rat IgG-PE (SouthernBiotech). For biotin-conjugated 
mRGMb mAb 9D1, 1.4 µg/ml of streptavidin-PE was used.
For receptor-ligand binding assay, mRGMb-, mPD-L2–, or mNeogenin-
transfected 300 cells, 300 cells, and hPD-1–transfected Jurkat T cells were 
stained with serial dilutions of specific protein-Ig or control-Ig plus 5 µg/ml 
of Fab2 goat anti–hIgG-PE (mouse-absorbed; SouthernBiotech), or 10 µg/ml 
of goat anti–mIgG2a-PE (SouthernBiotech), or 5 µg/ml of Fab2 goat anti-
mIgG2a-PE (SouthernBiotech).
To test the capacities of RGMb mAbs to block mRGMb binding to 
mNeogenin, RGMb-mIgG2a at 5 µg/ml was incubated with serial dilutions 
modality has the optimal balance of efficacy and minimal ad-
verse events. Treatment with PD-L2-Ig decreased murine TC-1 
lung tumor burden and increased survival, possibly by deple-
tion of T cells expressing high levels of PD-1 (Mkrtichyan 
et al., 2012); however, these PD-L2-Ig effects could also be 
through RGMb and the BBRN complex. Further studies are 
needed to determine if RGMb–PD-L2 interaction serves as a 
target for immunotherapy.
In summary, we discovered that RGMb is a binding partner 
for PD-L2. RGMb may coordinate with multiple receptors in 
the BMP and neogenin pathways to form a BBRN signaling su-
percomplex. Engagement of PD-L2 with RGMb in this super-
complex may impact BMP and neogenin signaling. We detected 
high mRNA levels of RGMb and components of the BBRN 
complex in resting lung IMs and AECs. Our data suggest that 
the novel engagement of RGMb and PD-L2 promotes the 
development of respiratory tolerance by facilitating the initial 
T cell expansion in draining LNs. Targeting the PD-L2 path-
way has therapeutic potential for asthma, cancer, and other im-
mune disorders, and may help better use the PD-1 pathway 
in cancer immunotherapy while minimizing adverse events.
MATERIALS AND METHODS
Mice. WT BALB/cJ mice and BALB/cByJ mice were purchased from The 
Jackson Laboratory. PD-L2/ mice on BALB/c background have been 
previously described (Keir et al., 2008). OVA TCR-transgenic DO11.10 mice 
and PD-L2/ mice crossed to OVA TCR-transgenic DO11.10 mice were 
used as donors of OVA-specific CD4+ T cells (Tsitoura et al., 1999). Age-
matched female mice were used at 6–12 wk. Animal protocols were approved 
by The Animal Care and Use Committees at Boston Children’s Hospital, the 
Dana-Farber Cancer Institute, and Harvard Medical School.
Cells and culture media. The mouse 300.19 pre–B cell line was trans-
fected by electroporation with mRGMb, hRGMb, or mNeogenin cDNA in 
the pEF-Puro expression vector. Cells were selected in media containing puro-
mycin, sorted, and subcloned. Cell surface expression of mRGMb, hRGMb, 
or mNeogenin was verified by flow cytometry using an mRGMb polyclonal 
antibody (R&D Systems), an hRGMb mAb (R&D Systems), or mRGMb-Ig, 
respectively. Other transfected cells, such as 300-mPD-L2, 300-mPD-L1, 
300-mPD-1, and Jurkat-hPD-1, have been made previously using similar 
methods. Cells were cultured in RPMI-1640 (Mediatech) supplemented 
with 10% heat-inactivated FBS (Invitrogen), 1% streptomycin/penicillin, 
15 µg/ml gentamicin (Invitrogen), 1% glutaMAX (Invitrogen), and 50 µM 
-mercaptoethanol (Sigma-Aldrich) at 37°C with 5% CO2.
The cell lines used in this study were purchased from American Type 
Culture Collection, except for SN12C which was obtained from the Na-
tional Cancer Institute. Mouse spleen or LN cells for tolerance experi-
ments were cultured in high-glucose DMEM (Invitrogen) supplemented with 
NEAA, sodium pyruvate, MEM vitamins, 10% FBS, 1% glutaMAX, 50 µM 
-mercaptoethanol at 37°C in a 10% CO2 incubator.
COS cell expression cloning of RGMb. A panel of murine-activated 
lymphocyte cDNA expression libraries were transiently transfected into COS 
cells using DEAE-Dextran or Lipofectamine as facilitator (Freeman et al., 1989). 
After 44 h, COS cells were harvested and panned on mPD-L2-mIgG2a/
IgA–coated Petri plates. Episomal DNA was recovered and electroporated 
into Escherichia coli DH10B/P3. Spheroplast fusion was used to reintroduce 
the plasmids into COS cells for subsequent rounds of expression and panning. 
Before the second and third rounds, COS cells expressing PD-1 were removed 
by incubating with PD-1 mAb, followed by depletion with goat anti–rat IgG 
magnetic beads. After the third round of panning, individual plasmids were 956 RGMb is a second receptor for PD-L2 | Xiao et al.
PD-L2-hIgG passed over the surface (R&D Systems; 25 µg/ml in 100 mM 
sodium acetate, pH 4.5), followed by blocking of free NHS ester with 1 M 
ethanolamine.  A  further  cell  was  exposed  to  immobilizing  reagents  and 
blocking reagents in the absence of protein as a control surface. After exten-
sive washing of the surfaces with binding buffer (10 mM Hepes, 150 mM 
NaCl, pH 7.0, and 0.05% Tween 20), PD-L2-hIgG fusion protein binding 
was assessed by injecting varying concentrations (0–658 nM) simultaneously 
over the control and RGMb flow cell surfaces. PD-1-hIgG (R&D Systems; 
4.8–308 nM) was similarly passed over immobilized PD-L2 and control sur-
faces. Between each cycle, the surface was regenerated using 20 mM glycine-
HCl, pH 2.8. Values shown in RU have been corrected for nonspecific 
binding by subtracting the SPR of the control flow chamber exposed to the 
same injected material, followed by subtraction of buffer alone passing over 
the RGMb or PD-L2 surface, respectively. Data were analyzed using BIA-
evaluation 3.2 software and fitted to a 1:1 Langmuir binding model with sepa-
rate kd and ka determinations. The dissociation constant (Kd) was determined 
as kd/ka, and confirmed by manual linear transformation of the binding iso-
therms. For PD-1 binding to PD-L2 surface, the kinetic parameters were de-
rived for monovalent binding of the Fc dimer at higher concentrations (red 
bar in Fig. 1 e), but data contributing to high-affinity bivalent interactions at 
lower concentrations were not included in the analysis.
Cell isolation and stimulation. Spleen and thymus cells were isolated by 
mechanically disrupting the tissues. For FACS analysis, splenocytes were treated 
with red blood cell lysing buffer (Sigma-Aldrich).
To obtain lung cells or splenocytes to analyze splenic DCs, the lung 
(perfused with PBS) or spleen was cut into small pieces, digested in RPMI 
1640 with 5% FBS, 1 mg/ml collagenase IV (Sigma-Aldrich), and 200 U/ml 
DNase  I  (Roche),  and  then  treated  with  red  blood  cell  lysing  buffer 
(Sigma-Aldrich).
Lung cell populations from naive mice were sorted by flow cytometry. 
Whole lung cells were isolated as above, and stained with surface markers. Cell 
populations were defined as follows: IMs (F4/80+CD11c), AMs (F4/80+ 
CD11c+), DCs (F4/80CD11c+; Bedoret et al., 2009), other cells (F4/80 
CD11c), CD4+ T cells (TCR+CD4+), CD8+ T cells (TCR+CD8+). IMs 
from OVA primed and challenged mice were identified as F4/80+CD11clow.
AECs and TECs were isolated from naive mice as described previously 
(Lam et al., 2011; Chuquimia et al., 2012). Thioglycollate-induced perito-
neal macrophages were obtained from mice on day 4 after i.p. injection with 
3% thioglycollate (DIFCO). CD4+ and CD8+ cells from mouse splenocytes 
were purified using CD4+ T cell isolation kit and CD8+ T cell isolation kit 
(Miltenyi Biotec). FLT-3L–stimulated splenocytes were obtained from mice 
2 wk after s.c. injection of FLT-3L–transfected RENCA tumor line.
qRT-PCR. Total RNA samples were isolated using the RNeasy mini kit 
(QIAGEN). Reverse transcription was performed using the QuantiTect re-
verse transcription kit (QIAGEN). qPCR using TaqMan gene expression 
assays (Applied Biosystems) was performed in a 7300 Real-Time PCR sys-
tem (Applied Biosystems). Fold change compared with GAPDH was calcu-
lated using the Ct method.
Western blotting. Cell lysates were prepared using RIPA buffer with com-
plete ULTRA protein inhibitors tablets (Roche). Lysates (60–80 µg/lane for 
cell lines and primary cells, and 0.5 or 1 µg/lane for RGMb-transfected 300 
cells) were run on SDS-PAGE under reducing conditions. Western blotting 
was performed using RGMb mAb 1H6 (10 µg/ml) plus goat anti–rat IgG-
HRP (Santa Cruz Biotechnology Inc.; 1:5,000). To blot for loading control, 
the membranes were treated with Restore Plus Western Blot Stripping Buf-
fer (Thermo Fisher Scientific) and blotted with mouse anti–mouse -actin 
(Abcam; 1:5,000) plus goat anti–mouse IgG-HRP (Santa Cruz Biotechnol-
ogy Inc.; 1:4000). Protein bands on the membranes were visualized using 
standard chemiluminescent techniques.
Immunohistochemistry  staining  and  confocal  microscopy. Cells 
were seeded on coverslips in culture medium the day before staining. Cells 
were fixed with 3.7% formaldehyde for 15 min at room temperature. After 
of RGMb mAbs, and then added to neogenin-transfected 300 cells. Binding 
was detected using 10 µg/ml of goat anti–mIgG2a-PE (SouthernBiotech). 
To determine the background binding, 300-mNeogenin cells were stained 
with serial dilutions of mIgG2a isotype control.
To assess cell surface expression of RGMb and PD-L2 on mouse cell 
lines RAW264.7, J774.1, and C2C12, cells were preincubated with mouse 
Fc receptor mAb (2.4G2), and then stained with PE-conjugated RGMb 
mAb 9D1, mPD-L2 mAb TY25, or rat IgG2a at 5 µg/ml.
To analyze cell surface expression of RGMb on human cancer cell 
lines, RGMb mAb 1H6 or rat IgG2a at 10 µg/ml plus goat anti–rat IgG-PE 
(SouthernBiotech) at 5 µg/ml were used.
For intracellular flow cytometry analyses of RGMb expression in primary 
cells from spleen, cells were first stained with LIVE⁄DEAD Fixable Near-IR 
(Invitrogen) at 1:1,000. After preincubation with mouse Fc receptor mAb 
(2.4G2), cells were stained with CD3-Pacific blue, CD19-PE-cy7 and CD11c-
APC (BioLegend). Then cells were permeabilized using BD Cytofix/Cy-
toperm Fixation/Permeabilization kit, preincubated with mouse Fc receptor 
mAb (2.4G2), and stained with PE-conjugated RGMb mAb 9D1 or rat IgG2a 
at 5 µg/ml. PBS containing 3% BSA and 0.1% Triton X-100 was used for wash 
and antibody incubation. 300-mPD-L2 cells were used as negative controls.
DO11.10 T cells were identified by staining with TCR-APC-eFluor 
780, CD4-PerCP, and KJ1-26-APC (eBioscience). DO11.10 T reg cells 
were identified using CD25-FITC (BioLegend), followed by intracellular 
staining with Foxp3-PE (BioLegend).
ELISA. To examine specificity of mRGMb mAbs, 96-well plates were coated 
with 2 µg/ml of recombinant mRGMa-HIS, mRGMb-HIS, or mRGMc-
HIS (R&D Systems). Then serial dilutions of mRGMb mAbs and isotype 
controls were added and incubated for 1 h at 37°C. Mouse anti–rat IgG 
(-specific) HRP (Jackson ImmunoResearch Laboratories) at 1:2,500 was 
used for detection.
To examine RGMa/RGMb/RGMc and PD-L2 interaction, 96-well 
ELISA plates were coated with 2 or 5 µg/ml of recombinant mRGMa-HIS, 
mRGMb-HIS, mRGMc-HIS, or hRGMb-HIS (R&D Systems). Then serial 
dilutions  of  mPD-L2-hIgG1/IgA,  mPD-L2-mIgG2a/IgA,  hPD-L2-
mIgG2a, or control-Ig fusion proteins were added and incubated for 1 h at 
37°C. Fab2 goat anti–hIgG-HRP (Jackson ImmunoResearch Laboratories) or 
rat anti–mIgG2a-HRP (BD) at 1:1,000 or 1:10,000 were used for detection.
To test the capacities of mRGMb antibodies and mPD-L2 fusion pro-
teins to block RGMb binding to BMP-2/4, 96-well ELISA plates were 
coated with 1 µg/ml of recombinant mouse BMP-2 (Invitrogen) or BMP-4 
(R&D  Systems).  mRGMb  antibodies,  isotype  controls,  mPD-L2-hIgG1/
IgA, mPD-L2-mIgG2a/IgA, or control Ig fusion proteins at the indicated 
concentrations were preincubated with 20 µg/ml mRGMb-HIS (R&D Sys-
tems) for 45 min at 4°C, then added to the plates and incubated for 1 h at 
37°C. Anti–penta-HIS-HRP (QIAGEN) at 1:1,000 was used for detection.
To determine if RGMb can bind PD-L2 and BMP-2/4 simultaneously, 
96-well ELISA plates were coated with BMP-2/4 as above. mPD-L2-hIgG1/
IgA, mPD-L2-hIgG (R&D Systems), mPD-L1-hIgG (R&D Systems), or 
control-Ig fusion proteins at 10 µg/ml were preincubated with 10 µg/ml 
mRGMb-HIS (R&D Systems) or buffer alone for 15 min at room tempera-
ture, and then added to the plates and incubated for 1 h at 37°C. Alternatively, 
10 µg/ml mRGMb-HIS (R&D Systems) or buffer alone was added first to 
the plates and incubated for 1 h at 37°C. After wash, mPD-L2-Ig or control-
Ig fusion proteins were added and incubated for 1 h at 37°C. Fab2 goat anti–
hIgG-HRP (Jackson ImmunoResearch Laboratories) at 1:10,000 was used 
for detection.
The substrate for HRP was TMB using the microwell peroxidase sub-
strate system (KPL).
Biacore. Interactions were determined by analysis of surface plasmon reso-
nance on a BIAcore 3000 instrument. Flow cells within a CM5 biosensor chip 
(GE Healthcare) were activated with N-hydroxysuccinimide (NHS) in the 
presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochlo-
ride, generating an NHS ester that bound to free amines on RGMb or JEM Vol. 211, No. 5  957
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ANOVA followed by Dunnett’s multiple comparisons test were performed 
using Prism version 6.00 for MacOS X (GraphPad Software). P < 0.05 was 
considered as significant. Data are mean ± SEM.
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three washes with PBS containing 0.5% BSA, cells were permeabilized 
in PBS containing 0.5% BSA and 0.5% Triton X-100 for 30 min. Endoge-
nous biotin was blocked with Endogenous Biotin-Blocking kit (Molecular 
Probes), followed by blocking in PBS containing 3% BSA and 0.1% Triton 
X-100 for 30 min at room temperature and three washes in PBS containing 
0.5% BSA and 0.1% Triton X-100. Cells were then incubated with biotin-
conjugated RGMb mAb 1H6 or biotin-conjugated rat IgG2a at 0.5 µg/ml 
in PBS containing 1% BSA and 0.1% Triton X-100 for 2 h at room tempera-
ture, followed by three washes as above. Subsequently, cells were incubated 
with Alexa Fluor 488–conjugated streptavidin (Jackson ImmunoResearch 
Laboratories) at 0.5 µg/ml in PBS containing 1% BSA and 0.1% Triton 
X-100 for 1 h at room temperature, followed by three washes as above. Finally, 
cells were stained with Phalloidin-TRIC (Sigma-Aldrich) at 50 µg/ml to 
label F-actin, and coverslips were mounted on slides with mounting media. 
Images were taken using a Nikon d-Eclipse C1 confocal microscope equipped 
with a Melles Griot 488 Ion Laser (with a 515/30 emission filter), a Melles 
Griot 543 Laser (with a 590/50 emission filter), a Melles Griot 640 Laser, and 
the Confocal Acquisition Software Nikon EZ-C1 version 3.90.
Respiratory tolerance and mAb treatment. To induce tolerance, lightly 
anesthetized WT BALB/cByJ or PD-L2/ mice received 100 µg of LPS-
free OVA (Worthington Biochemical) in PBS or PBS alone (control) by in-
tranasal instillation on days 0, 1, and 2. In some experiments, mice were 
treated with RGMb, PD-L2, PD-L1, or PD-1 blocking mAb or control anti-
body i.p. on day 1 (450 µg/mouse) and day 2 (200 µg/mouse). On day 12, mice 
were immunized with 50 µg OVA (ICN Biomedical) adsorbed in 2 mg 
ALUM. Spleens were harvested on day 19 and splenocytes or B cell–depleted 
splenocytes were restimulated in vitro with OVA. Cultures were pulsed with 
1 µCi of 3[H]-thymidine for the final 17 h and harvested at 96 h. Culture su-
pernatants were harvested at 96 h. IL-4, IFN-, and IL-5 were quantitated by 
ELISA. In some experiments, cells were labeled with CFSE before culture, 
stained on day 4 with CD3-PerCPCy5.5, and CD4-Alexa Fluor 700, and 
analyzed for CFSE dilution.
Measurement of airway hyperreactivity. Mice tolerized and immunized 
with OVA/ALUM i.p. as above were given OVA i.n. on day 20, 21, and 22. 
1 d after the final dose, mice were sedated, tracheostomized, and ventilated. 
Direct measurement of airway resistance and dynamic compliance was per-
formed by invasive plethysmography (BUXCO systems). Two pressure sen-
sors measured changes in lung volume and tracheal pressure in response to 
increasing concentrations of aerosolized methacholine. From these measure-
ments, average lung resistance was calculated for 3 min per dose of metha-
choline. For histopathology, lungs were flushed with PBS to remove blood, 
infused with 10% (vol/vol) formalin, and embedded in paraffin. 5-µm lung 
sections were cut and stained with hematoxylin and eosin.
Transfer of DO11.10 T cells and respiratory tolerance. T cells from 
DO11.10 or DO11.10 PD-L2/ mice were positively selected from spleens 
by incubating with CD4+ magnetic beads and sorting using MACS columns 
(Miltenyi Biotec). Each recipient received 2 × 105 or 5 × 106 DO11.10 T cells 
i.v., followed by 3 i.n. doses of 100 µg LPS-free OVA on days 0, 1, 2 and mAbs 
as indicated. Cells from mediastinal LNs were analyzed by flow cytometry 
on days 3, 5, and/or 7.
Evaluation of antibodies for in vivo cell depletion. To determine if 
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and DCs (F4/80CD11c+), and cell numbers of PD-L2+ and total cells were 
enumerated. In a separate experiment, mice were treated with RGMb mAb 
9D1 or isotype control and the same analysis was performed.
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